Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
BMC Vet Res. 2023 Sep 21;19(1):167. doi: 10.1186/s12917-023-03737-7.
High-flow nasal oxygen (HFNO) therapy is a non-invasive respiratory support method that provides oxygen-enriched, warmed, and humidified air to respiratory-compromised patients. It is widely used in human medical care, but in veterinary medicine it is still a relatively new method. No practical guidelines exist for its use in canine pneumonia patients, although they could potentially benefit from HFNO therapy. This study aims to provide a new, safe, non-invasive, and effective treatment protocol for oxygen supplementation of non-sedated dogs with pneumonia.
Twenty privately owned dogs with pneumonia will receive HFNO therapy at a flow rate of 1-2 L/kg, and the fraction of inspired oxygen will be determined individually (ranging from 21% to 100%). HFNO therapy will continue as long as oxygen support is needed based on clinical evaluation. Patients will be assessed thrice daily during their hospitalisation, with measured primary outcomes including partial pressure of oxygen, oxygen saturation, respiratory rate and type, days in hospital, and survival to discharge.
The proposed protocol aims to provide a practical guideline for applying HFNO to dogs hospitalised due to pneumonia. The protocol could enable more efficient and well-tolerated oxygenation than traditional methods, thus hastening recovery and improving survival of pneumonia patients.
高流量鼻氧（HFNO）治疗是一种非侵入性呼吸支持方法，为呼吸功能受损的患者提供富氧、加热和加湿的空气。它在人类医疗中得到广泛应用，但在兽医领域仍是一种相对较新的方法。尽管 HFNO 治疗可能对犬肺炎患者有益，但目前尚无针对其使用的实用指南。本研究旨在为非镇静犬肺炎的氧补充提供一种新的、安全的、非侵入性和有效的治疗方案。
20 只患有肺炎的私人拥有的犬将接受 HFNO 治疗，流速为 1-2 L/kg，并根据个体情况确定吸入氧分数（范围为 21%-100%）。根据临床评估，只要需要氧支持，HFNO 治疗将持续进行。患者在住院期间每天评估 3 次，测量的主要结果包括氧分压、氧饱和度、呼吸频率和类型、住院天数和出院存活率。
拟议的方案旨在为因肺炎住院的犬应用 HFNO 提供实用指南。该方案可以实现比传统方法更高效和耐受良好的氧合作用，从而加速肺炎患者的康复并提高其存活率。
Zotero 插件
